{"nct_id":"NCT02443324","title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","status":"COMPLETED","status_verified_date":"2024-02","start_date":"2015-07-29","start_date_type":"ACTUAL","primary_completion_date":"2018-08-31","primary_completion_date_type":"ACTUAL","completion_date":"2022-04-12","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["LLY"]}